Aspira Womens Health Inc
Aspira Women's Health Inc., together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitiv… Read more
Aspira Womens Health Inc (AWH) - Net Assets
Latest net assets as of December 2024: $-2.56 Million USD
Based on the latest financial reports, Aspira Womens Health Inc (AWH) has net assets worth $-2.56 Million USD as of December 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($5.49 Million) and total liabilities ($8.05 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-2.56 Million |
| % of Total Assets | -46.68% |
| Annual Growth Rate | N/A |
| 5-Year Change | -126.37% |
| 10-Year Change | -114.61% |
| Growth Volatility | 883.21 |
Aspira Womens Health Inc - Net Assets Trend (1998–2024)
This chart illustrates how Aspira Womens Health Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Aspira Womens Health Inc (1998–2024)
The table below shows the annual net assets of Aspira Womens Health Inc from 1998 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-2.56 Million | -8.37% |
| 2023-12-31 | $-2.37 Million | -135.14% |
| 2022-12-31 | $6.73 Million | -77.69% |
| 2021-12-31 | $30.17 Million | +210.44% |
| 2020-12-31 | $9.72 Million | +11.23% |
| 2019-12-31 | $8.74 Million | +22.18% |
| 2018-12-31 | $7.15 Million | +109.92% |
| 2017-12-31 | $3.41 Million | -9.44% |
| 2016-12-31 | $3.76 Million | -78.56% |
| 2015-12-31 | $17.55 Million | -8.88% |
| 2014-12-31 | $19.25 Million | -28.06% |
| 2013-12-31 | $26.77 Million | +473.52% |
| 2012-12-31 | $4.67 Million | -54.95% |
| 2011-12-31 | $10.36 Million | +124.42% |
| 2010-12-31 | $4.62 Million | +116.90% |
| 2009-12-31 | $-27.32 Million | +6.02% |
| 2008-12-31 | $-29.07 Million | -153.60% |
| 2007-12-31 | $-11.46 Million | -15.77% |
| 2006-12-31 | $-9.90 Million | -251.79% |
| 2005-12-31 | $6.52 Million | -75.58% |
| 2004-12-31 | $26.71 Million | -44.41% |
| 2003-12-31 | $48.06 Million | -29.73% |
| 2002-12-31 | $68.39 Million | -26.65% |
| 2001-12-31 | $93.23 Million | -17.61% |
| 2000-12-31 | $113.15 Million | +4005.66% |
| 1999-12-31 | $2.76 Million | +116.93% |
| 1998-12-31 | $-16.27 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Aspira Womens Health Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 53139700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $17.00K | % |
| Other Components | $528.82 Million | % |
| Total Equity | $-2.56 Million | 100.00% |
Aspira Womens Health Inc Competitors by Market Cap
The table below lists competitors of Aspira Womens Health Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Infinitum Copper Corp
OTCQB:INUMF
|
$664.88K |
|
NEXUS (NXU.SG)
STU:NXU
|
$666.09K |
|
Xplore Resources Corp.
PINK:XPRCF
|
$667.19K |
|
AMERICAN INTL GROUP - Dusseldorf Stock Exchang
DU:AINN
|
$667.58K |
|
Tali Digital Ltd
AU:TD1
|
$664.45K |
|
8PSB
XETRA:8PSB
|
$663.77K |
|
Conduit Pharmaceuticals Inc.
NASDAQ:CDT
|
$663.70K |
|
Loyal Solutions AS
ST:LOYAL
|
$663.22K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Aspira Womens Health Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -2,365,000 to -2,563,000, a change of -198,000.
- Net loss of 13,094,000 reduced equity.
- New share issuances of 8,377,000 increased equity.
- Other factors increased equity by 4,519,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-13.09 Million | -510.89% |
| Share Issuances | $8.38 Million | +326.84% |
| Other Changes | $4.52 Million | +176.32% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Aspira Womens Health Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1998-12-31 | $-4912.47 | $0.03 | x |
| 1999-12-31 | $430.83 | $0.03 | x |
| 2000-12-31 | $14587.08 | $0.03 | x |
| 2001-12-31 | $5274.63 | $0.03 | x |
| 2002-12-31 | $3802.30 | $0.03 | x |
| 2003-12-31 | $2551.65 | $0.03 | x |
| 2004-12-31 | $1370.28 | $0.03 | x |
| 2005-12-31 | $302.73 | $0.03 | x |
| 2006-12-31 | $-407.28 | $0.03 | x |
| 2007-12-31 | $-240.53 | $0.03 | x |
| 2008-12-31 | $-68.32 | $0.03 | x |
| 2009-12-31 | $-61.50 | $0.03 | x |
| 2010-12-31 | $6.65 | $0.03 | x |
| 2011-12-31 | $10.90 | $0.03 | x |
| 2012-12-31 | $4.66 | $0.03 | x |
| 2013-12-31 | $19.19 | $0.03 | x |
| 2014-12-31 | $8.00 | $0.03 | x |
| 2015-12-31 | $5.59 | $0.03 | x |
| 2016-12-31 | $1.08 | $0.03 | x |
| 2017-12-31 | $0.90 | $0.03 | x |
| 2018-12-31 | $1.53 | $0.03 | x |
| 2019-12-31 | $1.51 | $0.03 | x |
| 2020-12-31 | $1.45 | $0.03 | x |
| 2021-12-31 | $4.07 | $0.03 | x |
| 2022-12-31 | $0.87 | $0.03 | x |
| 2023-12-31 | $-0.26 | $0.03 | x |
| 2024-12-31 | $-0.18 | $0.03 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Aspira Womens Health Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -142.61%
- • Asset Turnover: 1.67x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-136.85%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1998 | 0.00% | -274.53% | 0.26x | 0.00x | $-6.42 Million |
| 1999 | -291.94% | -160.60% | 0.73x | 2.48x | $-8.32 Million |
| 2000 | -17.94% | -227.24% | 0.08x | 1.05x | $-31.62 Million |
| 2001 | -27.69% | -135.50% | 0.18x | 1.15x | $-35.13 Million |
| 2002 | -42.53% | -73.97% | 0.45x | 1.28x | $-35.91 Million |
| 2003 | -76.73% | -62.95% | 0.57x | 2.13x | $-41.54 Million |
| 2004 | -74.27% | -49.38% | 0.54x | 2.78x | $-22.51 Million |
| 2005 | -543.20% | -130.05% | 0.52x | 8.10x | $-36.09 Million |
| 2006 | 0.00% | -121.14% | 0.79x | 0.00x | $-21.08 Million |
| 2007 | 0.00% | -48368.18% | 0.00x | 0.00x | $-20.14 Million |
| 2008 | 0.00% | -14782.26% | 0.03x | 0.00x | $-15.42 Million |
| 2009 | 0.00% | -17780.65% | 0.03x | 0.00x | $-19.32 Million |
| 2010 | -412.35% | -1619.91% | 0.05x | 5.21x | $-19.50 Million |
| 2011 | -171.73% | -925.12% | 0.08x | 2.23x | $-18.83 Million |
| 2012 | -153.12% | -341.26% | 0.24x | 1.85x | $-7.61 Million |
| 2013 | -32.95% | -343.69% | 0.08x | 1.14x | $-11.50 Million |
| 2014 | -99.76% | -761.96% | 0.10x | 1.26x | $-21.13 Million |
| 2015 | -108.94% | -878.04% | 0.10x | 1.19x | $-20.87 Million |
| 2016 | -397.87% | -566.54% | 0.33x | 2.13x | $-15.34 Million |
| 2017 | -308.10% | -336.33% | 0.42x | 2.20x | $-10.84 Million |
| 2018 | -158.99% | -372.45% | 0.27x | 1.60x | $-12.09 Million |
| 2019 | -169.89% | -327.13% | 0.33x | 1.58x | $-15.72 Million |
| 2020 | -181.40% | -379.06% | 0.24x | 2.02x | $-18.60 Million |
| 2021 | -105.10% | -465.50% | 0.17x | 1.36x | $-34.73 Million |
| 2022 | -320.53% | -263.62% | 0.47x | 2.58x | $-22.25 Million |
| 2023 | 0.00% | -182.32% | 1.46x | 0.00x | $-16.45 Million |
| 2024 | 0.00% | -142.61% | 1.67x | 0.00x | $-12.84 Million |
Industry Comparison
This section compares Aspira Womens Health Inc's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $1,016,846,396
- Average return on equity (ROE) among peers: -24.72%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Aspira Womens Health Inc (AWH) | $-2.56 Million | 0.00% | N/A | $664.47K |
| Agilent Technologies Inc (A) | $4.08 Billion | 3.46% | 0.65x | $31.80 Billion |
| Amer Bio Medica (ABMC) | $3.38 Million | -26.64% | 1.08x | $3.55K |
| ADCNF (ADCNF) | $1.77 Billion | 2.65% | 1.64x | $172.01 Million |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.48 Billion | 0.00% | 0.87x | $1.68 Million |
| ANGLE plc (ANPCF) | $18.44 Million | -77.14% | 0.38x | $34.42 Million |
| SeqLL Inc. (ATLN) | $8.18 Million | -45.26% | 0.31x | $35.63K |
| Avricore Health Inc (AVCRF) | $2.20 Million | -79.50% | 0.04x | $3.22 Million |
| Biodesix Inc (BDSX) | $-198.03 Million | 0.00% | 0.00x | $50.38 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.79 Million | 0.00% | 0.00x | $5.08 Million |